Time changes, and the glory of the world is renewed day by day. Looking back on 2022, for Dahua Pharmaceutical, it was a year of unity and joint struggle, as well as a year of striving for innovation and development. This year, Dahua Pharmaceutical has withstood the severe test of epidemic control measures, undergone strict review by the World Health Organization, and embarked on a new journey of innovative development... Despite the ups and downs, Dahua Pharmaceutical remains determined to move forward.

In mid January, the overall construction of the 850 square meter new factory building for the technological renovation project was completed, and it successfully passed the GMP compliance testing for factory construction. Newly purchased equipment gradually entered the site. When preparing to carry out equipment verification and debugging work, the project was disrupted by the severe epidemic situation. In response to changes and circumstances, the Dahua Pharmaceutical project team actively formulated response strategies to minimize the impact of the epidemic on project progress. As of now, all production equipment is in place and equipment confirmation work is steadily underway.

At the end of March, Dahua Pharmaceutical strictly followed the government's epidemic prevention requirements and completely suspended production. It was not until the end of May, when the epidemic situation improved, that the company's production line pressed the "start button" to resume work and production. The two month long shutdown has a significant impact on the market of manufacturing enterprises. In order to stabilize the global market, all cadres and employees of the company worked together and fulfilled their respective duties. During the lockdown period, they maintained most of the orders and resumed work and production as soon as possible after the lifting of the lockdown. Within a week after the lifting of the lockdown, foreign orders were confirmed, achieving a good start to resumption of work and production.

In early October, Dahua Pharmaceutical underwent its first GMP review after obtaining PQ qualification. Upon receiving notification of the upcoming review, all departments were on high alert and fully prepared for the five-day inspection. During the re examination, personnel from various departments fully cooperated with the audit teacher, truthfully provided and answered the audit content, and completed the 5-day on-site and document review in a tense and orderly work arrangement. The audit results were satisfactory.

While focusing on economic benefits, Dahua Pharmaceutical also attaches great importance to improving its own soft power. With the continuous increase of patents obtained by the company, in order to avoid intellectual property risks and achieve standardized intellectual property management, the company has been preparing to establish an intellectual property management system since January. At the end of November, it underwent the first third-party certification audit and successfully passed the audit.

At the end of October, the company applied for the recognition of Chongming District Enterprise Technology Center and smoothly entered the list of proposed recognition. After enterprise defense, expert review, and comprehensive evaluation, Dahua Pharmaceutical was recognized as the 10th batch of district level enterprise technology centers in Chongming District in 2022, laying a good foundation for the company's high-quality and innovative development.

At the end of November, the company launched the application for the 2022 "Specialized, Refined, Unique and New" small and medium-sized enterprises. Specialized, refined, distinctive, and innovative "is not only an honorary qualification, but also the starting point for Dahua Pharmaceutical to truly embark on the path of specialization, refinement, specialization, and novelty.

Spring blossoms and autumn fruits have arrived once again, forging ahead and continuing a new chapter. In 2023, we will engrave our goals in our hearts, regard "execution" as an iron law, take "responsibility" as a consciousness, and show the drive, breadth, and perseverance to overcome difficulties and embark on a new journey of development in 2023.